Subitec GmbH, a manufacturer of fully automated algae photobioreactors, hascloseda second round of financing. The CleantechFonds of eCAPITAL entrepreneurial Partners AG, Fraunhofer Venture, High-Tech Gründerfonds (HTGF) [High-Tech Start-Up Fund] and KfWBankengruppe’s ERP-Startfonds [ERP Sta ... more
Subitec raises 4.5 m euros in second round financing
Subitec GmbH, a manufacturer of fully automated algae photobioreactors, hascloseda second round of financing. The CleantechFonds of eCAPITAL entrepreneurial Partners AG, Fraunhofer Venture, High-Tech Gründerfonds (HTGF) [High-Tech Start-Up Fund] and KfWBankengruppe’s ERP-Startfonds [ERP Start Fund] participated in the capital increase. Subitec funds to the amount of 4.5 m euros will accrue in this round of financing. The raised capital is to be used mainly for launching bioreactors on the international market and to extend technological leadership.
“Compared to other energy crops such as maize or wheat, algae are considerably more efficient in creating biomass. To exploit this potential, Subitec has developed highly efficient algae photobioreactors which permit the propagation of algae and the creation of algae biomass at competitive prices on an industrial scale. Together we would now like to encourage the further development of this innovative company”, says Dr Michael Lübbehusen, Managing Partner of eCAPITAL AG. The capital made available would enable Subitec to further extend its market position. Among other things, source materials for the chemical, pharmaceutical and food industries can be obtained from the microalgae.
Lübbehusen further adds that Subitec is making the fully automated operation of algae photobioreactors possible with its patented flat panel airlift process. The creation of biomass is not in competition with food production here. Subitec’s reactors can be operated at locations where no other form of farming is possible.
Subitec will use the funds from the capital increase among other things to develop the fourth generation of the flat panel airlift reactor (FPA). “The collaboration with our new investors enables us to address international markets and further extend our technological leadership”, explains Dr Peter Ripplinger, Managing Director of Subitec GmbH, on the occasion of the recent closing. Subitec was founded in 2000 as a spin-off of the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB.
The photobioreactor developed by Subitec GmbH enables efficient production of algae biomass on an industrial scale. Microalgae such as the freshwater algae Haematococcuspluvialis or the diatom Phaeodactylumtricornutum can for example provide fatty acids, proteins, vitamins, carotenoids and colorants. Among other things, these are needed as primary products for the production of cosmetics, food additives and animal feed.
Conventional algae cultivation in Asia takes place mainly in open ponds. The Subitec algae bioreactor in contrast allows land-based cultivation in closed bioreactors without water loss from evaporation. It can also be operated sterilely, i.e. under conditions essential for the pharmaceutical and cosmetics industries.
High-Tech Gründerfonds (HTGF) is investing EUR 600,000 in Reutlingen-based SIGNATOPE GmbH. SIGNATOPE will use the funds to advance the development of its unique biomarker assay system, that has been established to support pharmaceutical research. The technology is based on special antibodie ... more
KSK Diagnostics GmbH uses its isothermal amplification technology, KDx rITA®, for the development of molecular point-of-care tests to identify pathogens and antimicrobial resistance within 30 minutes. This significantly reduces the time before therapy is started. A financing round has now b ... more
The investors AURELIA, High-Tech Gründerfonds (HTGF), KfW, ILB, the venture capital fund of the Sparkassen of Brandenburg and Business Angels sell their GILUPI shares to the strategic partner VIROAD. GILUPI is a company developing and manufacturing personalized cancer diagnostics in Potsdam ... more
- 1Diamond detectors for CERN
- 2Groundbreaking experimental method will speed up protein analysis substantially
- 3We are much more unique than assumed
- 4PerkinElmer to acquire EUROIMMUN for approximately $1.3 Billion
- 5Shimadzu acquires specialist for isotope labeled standards
- 6New three-in-one blood test opens door to precision medicine for prostate cancer
- 7LAUDA appoints Dr. Ralf Hermann as the new General Manager Constant temperature equipment
- 8State-of-the-art text mining technologies for chemistry
- 9Eurofins expands its footprint in the Balkan region
- 10Waters Corporation elects Flemming Ornskov to Board of Directors
- Shimadzu acquires specialist for isotope labeled standards
- Groundbreaking experimental method will speed up protein analysis substantially
- We are much more unique than assumed
- LAUDA appoints Dr. Ralf Hermann as the new General Manager Constant temperature equipment
- PerkinElmer to acquire EUROIMMUN for approximately $1.3 Billion